Bortezomib (PS-341)

Catalog No.S1013

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Cited by 142 publications:

20 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF-7M2rhVmN6fG:2b4jpZ{BCe3OjeR?=MWC1NEDPxE1?NInnUGc1QCCqNHn3UYZFVVORM4XIV2tqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU>NFvDUlMyODR7OU[0Ny=>
OVCA 429NHj0W5VHfW6ldHnvckBCe3OjeR?=MUSzNFAhdk1?MV60PEBpM4jq[2ROW09?M2PIfmRqe3K3cITzJIlvfGGldDDteYx1cWOnbHz1cIFzKHS3bX;yJJNxcGW{b3nkdy=>MX2xNFk6QTd4Nh?=
RPMI8226MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\1RlExOCCwTR?=NGmzb481QCCqMmfxSG1UVw>?NEO3eItKSzVyPUOwJI5OM3qwS|EyOzB4NEi5
Dox40NW\oSldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjoXW5zOTByIH7NMVi0PEBpNI[2e|ZFVVORMV7JR|UxRTRyIH7NMmH0NVE{ODZ2OEm=
MR20NYTOSHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{X6elExOCCwTR?=M1fPZ|Q5KGh?MlX6SG1UVw>?MXPJR|UxRTJyIH7NNH7oUFQyOTNyNkS4PS=>
LR5NIfhO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYixNFAhdk1?NHL1UIg1QCCqMmjGSG1UVw>?MXTJR|UxRTJyIH7NM4DWelEyOzB4NEi5
U266MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXixNFAhdk1?MoqzOFghcA>?MlTYSG1UVw>?NF3DfoNKSzVyPUOgcm0>MVyxNVMxPjR6OR?=
IM-9NY\mZ3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfTdHJFOTByIH7NNFrNOYc1QCCqMXPEUXNQMlXTTWM2OD14IH7NNHy5fmQyOTNyNkS4PS=>
Hs SultanM1X6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HFSFExOCCwTR?=MWG0PEBpMXfEUXNQMk[5TWM2OD1{MDDuUS=>M2jtZ|EyOzB4NEi5
PAM-LY2NXXLeFc{TnWwY4Tpc44hSXO|YYm=MX[xNFAhdk1?NGDmSWsyOiCqM3jZZWROW09?NUjxNlhzUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44>MlPVNVE{PTB7MUO=
PAM 212NI[1fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XMOlExOCCwTR?=MXS3NkBpMmnKSG1UVw>?MYTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?NWXEcHc{OTF|NUC5NVM>
PAM-LY2MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W5clExOCCwTR?=Mon4O|IhcA>?NUfhVGhwTE2VTx?=MUnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?NUL0[I5tOTF|NUC5NVM>
B4B8Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHaSoIyODBibl2=M2O0W|czKGh?MX3EUXNQM3zHW2lvcGmkaYTzJINmdGxidnnhZoltcXS7NEHMUHkyOTN3MEmxNy=>
B7E3NWC5fYFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTLNVAxKG6PMn24O|IhcA>?M1LjPWROW09?NWDOPFAzUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=MYixNVM2ODlzMx?=
UM-SCC-9NVTqfppqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTpNVAxKG6PMlywO|IhcA>?MWTEUXNQM{TaTGlvcGmkaYTzJINmdGxidnnhZoltcXS7MkfUNVE{PTB7MUO=
UM-SCC-11BNXPnZmVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz1OFYyODBibl2=MoHFO|IhcA>?MXfEUXNQMmP4TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?NIXJenIyOTN3MEmxNy=>
H460MXXGeY5kfGmxbjDBd5NigQ>?MX[xNEDPxE1?MUKyOEBpM36wbWROW09?NGXrTJRKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2MV[xNlQ6OjFzNx?=
U266NXfOOpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XUTFUxOCCwZz;tcC=>MmHYOFghcA>?MX7EUXNQNHe4VFhKdmirYnn0d{Bk\WyuIHfyc5d1cA>?MkTHNVI3OzF4MUm=
ARH77Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPrOVAxKG6pL33sMmrBOFghcA>?MV\EUXNQMmLYTY5pcWKrdIOgZ4VtdCCpcn;3eIg>NI\GO3MyOjZ|MU[xPS=>
WAD-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3TOVAxKG6pL33sMlLOOFghcA>?NEXhPIhFVVORMlyxTY5pcWKrdIOgZ4VtdCCpcn;3eIg>MkiyNVI3OzF4MUm=
U266/LR7NYLYZYtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\nOVAxKG6pL33sMkmwOFghcA>?NGW0bmNFVVORNXvid|JCUW6qaXLpeJMh[2WubDDndo94fGh?M1\4bVEzPjNzNkG5
U266/dox4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfWOVAxKG6pL33sM1zxUVQ5KGh?NWLaS45YTE2VTx?=MYDJcohq[mm2czDj[YxtKGe{b4f0bC=>M{n2WVEzPjNzNkG5
RPMI8226/LR5M3fudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vSblUxOCCwZz;tcC=>M3z5d|Q5KGh?NFTIW|NFVVORNHv2NmlKdmirYnn0d{Bk\WyuIHfyc5d1cA>?NVHY[ZFEOTJ4M{G2NVk>
H460M{izcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDnd4syOCEQvF2=MnvPO|IhcA>?MWPEUXNQNWnVVm0zUUN3ME2xNFAhdk1?MnS1NVI3OzF4MkC=
H358NEmxc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWWxNEDPxE1?M{exb|czKGh?NUXHOHRMTE2VTx?=Mn;xTWM2OD15MDDuUS=>M{T0dFEzPjNzNkKw
H322M4LoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW[5NYVTOTBizszNMXm3NkBpMWnEUXNQMkLPTWM2OD14MkCgcm0>M1O0clEzPjNzNkKw
H460NEL3UlNHfW6ldHnvckBCe3OjeR?=NEWwPGUyODBibl2=NX;tO5lHOjRiaB?=NIjhUYpFVVORM{GxdGlv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl?M130XVEzPjNzNkKw
LNCap-Pro5NYqwPJBNTnWwY4Tpc44hSXO|YYm=NYLDe4gxOSEQvF2=MUC0JIg>NWjkcZF3TE2VTx?=NXfpO|hTW3SjYnnsbZpmeyCyNUO=MnjxNVQ3OTJ3M{K=
T29NGjoPGtCeG:ydH;zbZMhSXO|YYm=NWS3fGpvPTBibl2=NVvY[GRtPDhiaDC=NEXINohFVVORNFXCZWNKdmS3Y3XzJINmdGxiYYDvdJRwe2m|MluzNVY4PzhzN{m=
T29Kt1NILZPXRCeG:ydH;zbZMhSXO|YYm=Ml7SOVAhdk1?NF3PPFk1QCCqIB?=NIfrNG1FVVORNETHcWJKdmS3Y3XzJINmdGxiYYDvdJRwe2m|NYXCb4VvOTZ5N{ixO|k>
HCT116NIrPN2hCeG:ydH;zbZMhSXO|YYm=NVXsRo5[PTBibl2=NF3FUpc1QCCqIB?=Mn\VSG1UVw>?NGrOSY5KdmS3Y3XzJINmdGxiYYDvdJRwe2m|NWDHWmpwOTZ5N{ixO|k>
HKe-3NVixeIFFSXCxcITvd4l{KEG|c3H5NGf6TI82OCCwTR?=NX\tXYs2PDhiaDC=M1nYWmROW09?NGLqbHBKdmS3Y3XzJINmdGxiYYDvdJRwe2m|M17pNVE3Pzd6MUe5
NB-1691M32yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXqWWh4OSEQvF2=M3;JTlczKGh?NHrkd|hKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW=NW\YbmdzOTd4OEm2PFQ>
CHLA-255MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfoWlgyKM7:TR?=M3L4PVczKGh?NVLRSVZzUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKlMWexO|Y5QTZ6NB?=
SK-N-ASNV7FSIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Pre|Eh|ryPMkXPO|IhcA>?MVPJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBnMWSxO|Y5QTZ6NB?=
NB-1691M1jzemZ2dmO2aX;uJGF{e2G7Mn3ONVAhdk1?NGjxRpYzPCCqMV;TbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPlMnrMNVc3QDl4OES=
CHLA-255Mn3wSpVv[3Srb36gRZN{[Xl?NIPn[VAyOCCwTR?=MWCyOEBpMnTPUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V?MkC2NVc3QDl4OES=
RPMI 8226MX\GeY5kfGmxbjDBd5NigQ>?NXjwT|lROjBibl2=MVi4JIg>M33DRnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6NVe2No5wOTl2M{[wOVA>
MM.1SM2PvSWZ2dmO2aX;uJGF{e2G7NXzvS4FVOjBibl2=NF;YbmU5KGh?NWfNdFBEW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?NFPEWIYyQTR|NkC1NC=>
U266MWnGeY5kfGmxbjDBd5NigQ>?NV3xOlJDOjBibl2=MXW4JIg>M2TEeHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6NHHab2gyQTR|NkC1NC=>
OPM1MoHFSpVv[3Srb36gRZN{[Xl?NHfDSmczOCCwTR?=NUfKfmJkQCCqNYfkVFV5W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?MX[xPVQ{PjB3MB?=
INA6NFu5UnJHfW6ldHnvckBCe3OjeR?=M3SwSFIxKG6PNVfWeXFOQCCqMXvTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>MlP2NVk1OzZyNUC=
OPM2MV3GeY5kfGmxbjDBd5NigQ>?NHr4VYgzOCCwTR?=MXG4JIg>NW\nb2QzW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?M4jQcVE6PDN4MEWw
RPMI 8226MVXGeY5kfGmxbjDBd5NigQ>?NFLlNo8zOCCwTR?=MWi4JIg>NYjMSJYzUW6mdXPld{BFVkFic4nueIhme2m|MWmxPVQ{PjB3MB?=
BaF/3MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYKxNFAhdk1?MlTLOFghcA>?MX7JR|UxRTZwMjDuUS=>NVrLO|d4OjB|MEW2PVI>
BaF/3-p210NX3SU4l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzXNVAxKG6PNWO4WZREPDhiaB?=MkXZTWM2OD12Lkegcm0>NEW3RWgzODNyNU[5Ni=>
TCC-SM4DOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXSxNFAhdk1?NEHXNno1QCCqM{DuOGlEPTB;Mj64JI5OMlfONlA{ODV4OUK=
BaF/3MXzGeY5kfGmxbjDBd5NigQ>?MYq2JI5ONXvUOo5QPDhiaB?=MlXrTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0NW\Db|Y3OjB|MEW2PVI>
BaF/3-p210NF;wbHRHfW6ldHnvckBCe3OjeR?=M2DZSlYhdk1?MkLMOFghcA>?NF23OZFKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1MlvaNlA{ODV4OUK=
BaF/3-p210NYK4NINmTnWwY4Tpc44hSXO|YYm=NWfkSWZ7PiCwTR?=MXeyOEBpM{DxWXJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKkNU\UeHF3OjB|MEW2PVI>
RajiMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[xO3AyKM7:TR?=NYPBUWxHOjRiaB?=MUjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?M1S2TVIyOTdyOUi4
LCL-1M17hSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWi0THl6OSEQvF2=NInI[Y8zPCCqMXPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MnjONlEyPzB7OEi=
LCL-2M1jJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDqemcyKM7:TR?=NXHuclZYOjRiaB?=M1Tv[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NGX3XZYzOTF5MEm4PC=>
BJABNEXaRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVKxJO69VQ>?MmP2NlQhcA>?M13id3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=MlP6NlEyPzB7OEi=
SNT-13NWH2dlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnZNUDPxE1?MXWyOEBpNFLDb|FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=NG\RO5czOTF5MEm4PC=>
SNT-16NV;yWIxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFToUFEyKM7:TR?=MViyOEBpNV:yVm1SWmWmdXPld{Bk\WyuII\pZYJqdGm2edMgMoLNNlEyPzB7OEi=
JurkatM3zpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfyXm5DOSEQvF2=NV3FcIxKOjRiaB?=MUPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?NIfae2EzOTF5MEm4PC=>
KAI-3NIPjPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHGzU5cyKM7:TR?=NH7QN|UzPCCqM2HnSHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=M3vhUFIyOTdyOUi4
SNK-6NEXQS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\WcVEh|ryPMm\aNlQhcA>?MoDCVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiMVeyNVE4ODl6OB?=
KHYG-1NWLlS|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfTe3EyKM7:TR?=NHiyblIzPCCqMVnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MVSyNVE4ODl6OB?=
SNT-16M1nzXWFxd3C2b4Ppd{BCe3OjeR?=NX;4TJQ5OSEQvF2=MYi2JIg>M{XLUWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?NXXJZ5BWOjFzN{C5PFg>
JurkatMmjmRZBweHSxc3nzJGF{e2G7NFW2ZY0yKM7:TR?=MX[2JIg>MVzJcoR2[2W|IHPlcIwh[XCxcITvd4l{NYnufVBxOjFzN{C5PFg>
KAI-3NVz4XG1qSXCxcITvd4l{KEG|c3H5NVXKVZhoOSEQvF2=MnTpOkBpNELERnFKdmS3Y3XzJINmdGxiYYDvdJRwe2m|NE\wPJEzOTF5MEm4PC=>
KHYG-1MUDBdI9xfG:|aYOgRZN{[Xl?NVvTWIhKOSEQvF2=NI\1TZc3KGh?NWTaR4V7UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=NWex[JdOOjFzN{C5PFg>
SNT-13NVHpR3NvSW62aY\pdoFtKEG|c3H5Ml36NUDPxE1?MmS4NlQhcA>?NWfJVYpqUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKYM4HmcVIyOTdyOUi4
SNT-16MV3BcpRqfmm{YXygRZN{[Xl?M4\6b|Eh|ryPMoW2NlQhcA>?MkPiTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJXNGrYSnQzOTF5MEm4PC=>
KAI-3NGnnTIRCdnSrdnnyZYwhSXO|YYm=NGHPemgyKM7:TR?=NIXPVmQzPCCqM2TDbGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?NHPE[WozOTF5MEm4PC=>
SNK-6M{Cy[mFvfGm4aYLhcEBCe3OjeR?=NHPjRYIyKM7:TR?=NW[4U3cxOjRiaB?=M2rue2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?NXv4c2dbOjFzN{C5PFg>
RAW 264.7MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGO4RpQyODBibl2=NXz2T5FVPDhiaB?=MV;S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?NXHufYc3OjJ2MkexOVQ>
A375M2LkbWFxd3C2b4Ppd{BCe3OjeR?=Mn7MNVAhdk1?M1zKdFI1KGh?MlfYTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?M4LqRVI{ODd7MEiz
BLMNGPpW|NCeG:ydH;zbZMhSXO|YYm=NI\hO|EyOCCwTR?=M2XYc|I1KGh?NY\EZ4VmUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=Ml71NlMxPzlyOEO=
A375NEjEcXNCfXSxcHjh[5khSXO|YYm=Mlz2NVAhdk1?NUK2SmtkOTJiaB?=NWjDW|J1UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>NIXjOXQzOzB5OUC4Ny=>
BLMMWnBeZRweGijZ4mgRZN{[Xl?NXfaZ242OTBibl2=M2HNTFEzKGh?MmPkTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=MX[yN|A4QTB6Mx?=
H1299MkfyRZBweHSxc3nzJGF{e2G7NWTWUHdoQDBibl2=MVWyOEBpMk\RSG1UVw>?MYHT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>?NUnUWGdWOjV|MkO2PVM>
Hut-78M1jrfGZ2dmO2aX;uJGF{e2G7MlTpNVAxKG6PMn3mNlQhcA>?MY\EUXNQNVyzVpNkTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;uNHHIR4ozPTZ6MUOzOS=>
H9MULGeY5kfGmxbjDBd5NigQ>?MkTuNVAxKG6PMk\mNlQhcA>?NGTkW3JFVVORMl\1SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:wNHzpbGUzPTZ6MUOzOS=>
HHMULGeY5kfGmxbjDBd5NigQ>?M{jvS|ExOCCwTR?=M3i1V|I1KGh?MUDEUXNQMUjkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25?NHfhPGYzPTZ6MUOzOS=>
Hut-78NHXr[m9OcWe{YYTpc44hSXO|YYm=NEOxVVQyODBibl2=MonVNlQhcA>?MkX5SG1UVw>?MUXS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBnNG[5N20zPTZ6MUOzOS=>
HHNH;DZ|hOcWe{YYTpc44hSXO|YYm=M1zLdlExOCCwTR?=NXLON24yOjRiaB?=MXHEUXNQMkDWVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?=NFLJT3AzPTZ6MUOzOS=>
U937M{LWWWZ2dmO2aX;uJGF{e2G7NYfZWoNKOTByIH7NMYe2JIg>M3jER2lv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN?MVKyOVc6OTR5Nx?=
human PBMCMUDGeY5kfGmxbjDBd5NigQ>?NIPLeFgyODBibl2=M1LWRVI1KGh?NH7hWGlKdmS3Y3XzJGlNNThicnXs[YF{\Q>?NFLxeYczPTd7MUS3Oy=>
ES6MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{CwNmlEPTB;MD6wNFIyKG6PM33ZOHNCVkeHUh?=
SK-UT-1M3TOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIOwNmFKSzVyPUCuNVY{KG6PNVTtWYVDW0GQR1XS
SH-4NVLtb3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\TTWM2OD1yLkG3N{BvVQ>?NHfROHpUSU6JRWK=
TE-9MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTBwMUiyJI5OMX3TRW5ITVJ?
A253MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwMkC4JI5OM3XOTnNCVkeHUh?=
no-10NEnIbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fYNmlEPTB;MD6yNUBvVQ>?NFzFNJZUSU6JRWK=
MMAC-SFNIG0dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mni1TWM2OD1yLkKxOkBvVQ>?NXPm[IwyW0GQR1XS
A101DM4iwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;OTWM2OD1yLkKyOUBvVQ>?MoDrV2FPT0WU
NTERA-S-cl-D1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwMkSzJI5ONGOzT41USU6JRWK=
8-MG-BANUTHZ486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrlZ4tKSzVyPUCuNlUhdk1?M3LkR3NCVkeHUh?=
KNS-42M4rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwMkW4JI5ONHvCOGZUSU6JRWK=
LXF-289Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrhZVk3UUN3ME2wMlI3QSCwTR?=MnzTV2FPT0WU
OVCAR-4NFHKOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwMki5JI5OMkXSV2FPT0WU
LOUCYNE[2O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NET3doVKSzVyPUCuNlk{KG6PNYfNSHJHW0GQR1XS
BB65-RCCMmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofYTWM2OD1yLkOwOEBvVQ>?MmH6V2FPT0WU
D-542MGMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rwT2lEPTB;MD6zNlkhdk1?MUPTRW5ITVJ?
ONS-76MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwM{Ogcm0>Ml3aV2FPT0WU
BB30-HNCNX:2TXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX5TWM2OD1yLkOzOUBvVQ>?MYHTRW5ITVJ?
KS-1M1nlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4K5XGlEPTB;MD6zOEBvVQ>?MlrUV2FPT0WU
A388MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwM{W2JI5ONVHLTW1MW0GQR1XS
ES8NVGxPYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfzTWM2OD1yLkSgcm0>NEXH[2pUSU6JRWK=
MZ2-MELNXOzdpVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTBwNEC3JI5ONXXEbXJpW0GQR1XS
HCC2998M1rOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TaemlEPTB;MD60NVIhdk1?MlnvV2FPT0WU
D-247MGNWrFOVFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1G4PGlEPTB;MD60NVMhdk1?NW[ySFRsW0GQR1XS
ACNMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXpTWM2OD1yLkSxO{BvVQ>?MV7TRW5ITVJ?
LB2518-MELMnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnp[VRjUUN3ME2wMlQzPSCwTR?=NHq5bFdUSU6JRWK=
ES1NWHWTVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwNEOgcm0>M2TjWXNCVkeHUh?=
HCE-TM4jDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTBwNEO5JI5OMWjTRW5ITVJ?
OS-RC-2MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwNESgcm0>NESwXJpUSU6JRWK=
MFH-inoM{XRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnyTWM2OD1yLkS0N{BvVQ>?NGSzSmlUSU6JRWK=
OCUB-MNHrnV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jYdGlEPTB;MD60OFchdk1?M4DLb3NCVkeHUh?=
CP66-MELNV\Y[I9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PReGlEPTB;MD60O|Mhdk1?NWLENXdpW0GQR1XS
LB771-HNCNIrkcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzETWM2OD1yLkS3OEBvVQ>?NInFN5pUSU6JRWK=
DSH1NFTufYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjqc2lKSzVyPUCuOFghdk1?M1vqeXNCVkeHUh?=
HUTU-80MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvHTWM2OD1yLkWzN{BvVQ>?NVPrTVRkW0GQR1XS
CESSMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3KzXWlEPTB;MD61N|ghdk1?MlH2V2FPT0WU
NCI-H747NIDETo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXsTGF1UUN3ME2wMlU{QSCwTR?=MYXTRW5ITVJ?
HT-144NWPseZViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL6Zm5wUUN3ME2wMlU4PiCwTR?=NX\4UlR[W0GQR1XS
COLO-829NHzBUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nqU2lEPTB;MD62NVQhdk1?M2\LS3NCVkeHUh?=
A4-FukNYjhN4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPVeW81UUN3ME2wMlYzOyCwTR?=NXrHXmNvW0GQR1XS
GI-ME-NMlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPGTnVKSzVyPUCuOlM1KG6PMkTtV2FPT0WU
LB831-BLCMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTBwNkSxJI5OM1r2Z3NCVkeHUh?=
HOP-62MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjjVYVMUUN3ME2wMlY1PyCwTR?=MVLTRW5ITVJ?
BB49-HNCNY\1fG9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2C5PWlEPTB;MD62OVIhdk1?NFHrdINUSU6JRWK=
D-336MGNHzlb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwNkW3JI5OM3rZOHNCVkeHUh?=
TK10M1LKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTjTWM2OD1yLk[3PUBvVQ>?M1SxdXNCVkeHUh?=
Ramos-2G6-4C10NEHse4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTBwNkmzJI5OMYPTRW5ITVJ?
LB373-MEL-DNIjvSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVK2NnZLUUN3ME2wMlchdk1?MVLTRW5ITVJ?
SF126MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrmepFuUUN3ME2wMlcxOSCwTR?=MVLTRW5ITVJ?
UACC-257NUnsU2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnxTWM2OD1yLkexJI5OMl7IV2FPT0WU
KINGS-1NWHEfmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPocWh2UUN3ME2wMlczOiCwTR?=MofLV2FPT0WU
LS-513NHTFXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1f5VWlEPTB;MD63N|khdk1?NYi0T3k2W0GQR1XS
GI-1M1n3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnVcIdKSzVyPUCuO|Y1KG6PMnTBV2FPT0WU
ES7NHjBWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXO[mVZUUN3ME2wMlc3PiCwTR?=MkfxV2FPT0WU
LB2241-RCCNUDPWYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly5TWM2OD1yLkiwOEBvVQ>?NE\veFZUSU6JRWK=
D-263MGNXfSZ4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTBwOEC3JI5OM3XVbnNCVkeHUh?=
SW684MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\ofGlEPTB;MD64NlEhdk1?NXTrU5AyW0GQR1XS
ML-2M3;oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXeyWXFkUUN3ME2wMlgzOSCwTR?=NGPoV5lUSU6JRWK=
SK-LMS-1NFn0O5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDNd5BKSzVyPUCuPFU1KG6PMWTTRW5ITVJ?
TE-5NWXUZ5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme5TWM2OD1yLki2OUBvVQ>?MVXTRW5ITVJ?
QIMR-WILNGOxZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nFOGlEPTB;MD64PFkhdk1?MkDRV2FPT0WU
NCI-H1355NEHCbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XMSmlEPTB;MD64PVUhdk1?MlfYV2FPT0WU
SNB75NFe3fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzLTHZKSzVyPUCuPVEzKG6PNV2x[m9IW0GQR1XS
RXF393NF\2fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYOwRWptUUN3ME2wMlkyPCCwTR?=Mn;PV2FPT0WU
IST-MEL1NVnkdGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TXdWlEPTB;MD65NVchdk1?NGXjN5JUSU6JRWK=
SF268NEHRZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnQeWhOUUN3ME2wMlkzOyCwTR?=NYTxbYFnW0GQR1XS
KALS-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn0c|dKSzVyPUCuPVI2KG6PM1Tz[nNCVkeHUh?=
HC-1M2O1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTBwOUe1JI5OMk\JV2FPT0WU
SW872MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\xTWM2OD1yLkm5OkBvVQ>?M2rXPXNCVkeHUh?=
PSN1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{j4e2lEPTB;MT6wNUBvVQ>?M4CzRnNCVkeHUh?=
TE-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTFwMEOgcm0>MUfTRW5ITVJ?
TE-10MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTRdVZKSzVyPUGuNFMhdk1?MoDRV2FPT0WU
RKONI\sOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnzWHRKSzVyPUGuNFYhdk1?MX7TRW5ITVJ?
LC-2-adNVjKRY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjtfI5KSzVyPUGuNFghdk1?M33yR3NCVkeHUh?=
SK-MM-2NHLOc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvUZ2ZxUUN3ME2xMlA6KG6PNI\tNYtUSU6JRWK=
VA-ES-BJM3rrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG5OVFKSzVyPUGuNFkhdk1?NF7tfGVUSU6JRWK=
MZ7-melM2\qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUD5SoM1UUN3ME2xMlA6KG6PMnzsV2FPT0WU
D-392MGMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrxTGxKSzVyPUGuNUBvVQ>?NEfjVXVUSU6JRWK=
CCRF-CEMNXO4Spl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2r1OmlEPTB;MT6xN{BvVQ>?MXPTRW5ITVJ?
EM-2M3THb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTLTWM2OD1zLkG2JI5ONInMUIlUSU6JRWK=
HAL-01NX;3bWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzWVldIUUN3ME2xMlE5KG6PNYLIPFZKW0GQR1XS
TE-8MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HmW2lEPTB;MT6xPUBvVQ>?M2eydHNCVkeHUh?=
NCI-H1882NFzMZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2wd3l6UUN3ME2xMlIhdk1?Mn;UV2FPT0WU
DaudiMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkT4TWM2OD1zLkKyJI5OMkLHV2FPT0WU
BL-41NITQfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\RSmlEPTB;MT6yOUBvVQ>?M1TZcXNCVkeHUh?=
SRNEGzUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrNc5M2UUN3ME2xMlI2KG6PNVGzWJpvW0GQR1XS
KM12MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nIdWlEPTB;MT6yO{BvVQ>?MXvTRW5ITVJ?
K5M3HoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\NVop1UUN3ME2xMlI5KG6PNVnBXmNbW0GQR1XS
A3-KAWMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf0TWM2OD1zLkK4JI5ONWDwS4M5W0GQR1XS
CMKM2WxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PmSmlEPTB;MT6yPUBvVQ>?MnHtV2FPT0WU
Calu-6M{XtW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjVTWM2OD1zLkK5JI5OMkDBV2FPT0WU
IST-SL2M1TBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm[3TWM2OD1zLkOxJI5OMnPlV2FPT0WU
OPM-2Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PxemlEPTB;MT6zN{BvVQ>?MlLTV2FPT0WU
DU-4475M3\nXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLyTWM2OD1zLkO2JI5OMmnDV2FPT0WU
ECC12M1qx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHRTWM2OD1zLkO3JI5ONEjx[5VUSU6JRWK=
L-540NUjuNYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXjU2tKSzVyPUGuN|chdk1?MYHTRW5ITVJ?
CAS-1NVvSfFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnsTWM2OD1zLkO3JI5OMm\rV2FPT0WU
PF-382NIf4cIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq2VZkyUUN3ME2xMlQ4KG6PM2\1eHNCVkeHUh?=
LS-411NNHm3epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe4W5ExUUN3ME2xMlU{KG6PM3;INHNCVkeHUh?=
NCI-H69MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwNUSgcm0>MXHTRW5ITVJ?
NB12MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\BNWlEPTB;MT61OkBvVQ>?MUXTRW5ITVJ?
HELM{fQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGCzO3BKSzVyPUGuOlEhdk1?M2W0NnNCVkeHUh?=
GCIYMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTFwNkKgcm0>MVPTRW5ITVJ?
EHEBNUfL[WpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PwZmlEPTB;MT62O{BvVQ>?NGj3ZndUSU6JRWK=
TGBC1TKBM2rjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX6bpNKSzVyPUGuO|Ehdk1?NE\jfIxUSU6JRWK=
KURAMOCHIMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDaNpFKSzVyPUGuO|Ihdk1?Mk\yV2FPT0WU
U-266M4qxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLW[2JKSzVyPUGuO|Yhdk1?M1rCdnNCVkeHUh?=
LC4-1MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTFwN{mgcm0>M4jyVnNCVkeHUh?=
NCI-H2126NYrxV4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPQTWM2OD1zLkigcm0>MlXFV2FPT0WU
NCI-H1092MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTFwODDuUS=>NXHi[3RDW0GQR1XS
GB-1M1vQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTFwOEGgcm0>NWna[JROW0GQR1XS
MV-4-11MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nydGlEPTB;MT64NkBvVQ>?M1PGenNCVkeHUh?=
BeckerNHjhPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4i0UmlEPTB;MT64N{BvVQ>?MYHTRW5ITVJ?
MPP-89MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HEU2lEPTB;MT64PUBvVQ>?M2G4U3NCVkeHUh?=
BE-13M{fSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHBTWM2OD1zLkmzJI5OM1m5PXNCVkeHUh?=
697M3TtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFwOUmgcm0>NEHJU3ZUSU6JRWK=
NKM-1M1zKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTaTWM2OD1{IH7NNGHrO2dUSU6JRWK=
NB13MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorsTWM2OD1{IH7NM2\vdXNCVkeHUh?=
LS-123MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTJwMEKgcm0>NXzFSVhKW0GQR1XS
NB17MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDmTWM2OD1{LkC0JI5OMnPMV2FPT0WU
LAN-6MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrZfI51UUN3ME2yMlA2KG6PM4G3XXNCVkeHUh?=
EW-24MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4L1S2lEPTB;Mj6wPEBvVQ>?NF;SXnlUSU6JRWK=
NOS-1M13YeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33SPGlEPTB;Mj6xNUBvVQ>?M2fTOnNCVkeHUh?=
BL-70NH2zRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[wcHl2UUN3ME2yMlEzKG6PNUnIfJd5W0GQR1XS
GT3TKBNXzvPG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJwMUKgcm0>MXzTRW5ITVJ?
HHNEfv[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHuTWM2OD1{LkGzJI5ONGLIOJRUSU6JRWK=
KE-37M3HGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJwMUOgcm0>M{XoZ3NCVkeHUh?=
MOLT-4NYnCWWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTJwMUOgcm0>NYG2[3dnW0GQR1XS
EKVXMlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXFcFdXUUN3ME2yMlE1KG6PMlLOV2FPT0WU
KGNM2e3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\vcW1pUUN3ME2yMlE2KG6PNHqyOJZUSU6JRWK=
ES4NETXd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3[2UGlEPTB;Mj6xOkBvVQ>?MkLNV2FPT0WU
SJSA-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHRU2dKSzVyPUKuNlEhdk1?MXjTRW5ITVJ?
KMOE-2NXPDOGV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4q3bGlEPTB;Mj6yN{BvVQ>?NI\EUpJUSU6JRWK=
NB5M{i4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PWemlEPTB;Mj6yO{BvVQ>?NYe5SVNxW0GQR1XS
BC-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTJwM{Ggcm0>M3PaVnNCVkeHUh?=
NB10MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rFZ2lEPTB;Mj6zNkBvVQ>?NHnh[3dUSU6JRWK=
RPMI-8226NHLFcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXz1U4NYUUN3ME2yMlM2KG6PM17XbXNCVkeHUh?=
SCC-3M{PHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fmdWlEPTB;Mj6zO{BvVQ>?NVX2cHlZW0GQR1XS
ARH-77NWTlTpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnuTWM2OD1{LkO4JI5ONFrCNHlUSU6JRWK=
NCI-H748NIr2NJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXsN4tYUUN3ME2yMlM6KG6PMVzTRW5ITVJ?
KU812M3:5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Gy[mlEPTB;Mj60NkBvVQ>?NFLXdpJUSU6JRWK=
NCI-H64NIPoVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHpd5dKSzVyPUKuOFQhdk1?MV;TRW5ITVJ?
NB69NXyx[FdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjD[|ZKSzVyPUKuOFYhdk1?NFzLW41USU6JRWK=
KNS-81-FDNXTHeXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4P0dWlEPTB;Mj60PEBvVQ>?MmC4V2FPT0WU
LB1047-RCCNWPY[FV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYX2N5VCUUN3ME2yMlU4KG6PNIrYRVVUSU6JRWK=
EB-3NVXjcpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TrPWlEPTB;Mj62OkBvVQ>?MXnTRW5ITVJ?
Mo-TNXi2bGljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGH4OJhKSzVyPUKuO|Qhdk1?MX;TRW5ITVJ?
EW-16M1fFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDEO2hrUUN3ME2yMlc2KG6PMYnTRW5ITVJ?
CTV-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;MNmlEPTB;Mj64JI5ONXvtNXlTW0GQR1XS
ETK-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37wRWlEPTB;Mj64OEBvVQ>?MYfTRW5ITVJ?
C2BBe1NYnaOIVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1j3[GlEPTB;Mj64PUBvVQ>?MUfTRW5ITVJ?
MOLT-16NUTxdoZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTJwOEmgcm0>NYi3WJRiW0GQR1XS
SW954M1u1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXScG9rUUN3ME2yMlkhdk1?MWHTRW5ITVJ?
HTNGflVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWH5WplmUUN3ME2zMlAzKG6PM1TET3NCVkeHUh?=
KARPAS-299NGroUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u3cmlEPTB;Mz6wOkBvVQ>?NITWVXRUSU6JRWK=
MONO-MAC-6M3T0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\YS496UUN3ME2zMlEhdk1?M2j3WnNCVkeHUh?=
CGTH-W-1NYH0R4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fiXWlEPTB;Mz6xJI5OM1vqN3NCVkeHUh?=
SK-PN-DWMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUS1OVJPUUN3ME2zMlE1KG6PM2TPR3NCVkeHUh?=
CW-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojjTWM2OD1|LkKxJI5OMojRV2FPT0WU
SK-N-DZMlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPwcoN[UUN3ME2zMlI3KG6PNGrEN5BUSU6JRWK=
NEC8MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUC5NHlCUUN3ME2zMlM2KG6PMn7TV2FPT0WU
LB996-RCCMlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTNwNDDuUS=>NXrIUWVRW0GQR1XS
DBM{DGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TXTWlEPTB;Mz60NUBvVQ>?MVvTRW5ITVJ?
TE-15M{nNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIT3SIpKSzVyPUOuOFMhdk1?MnLkV2FPT0WU
COR-L88NV3te2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTNwNEegcm0>M2jjN3NCVkeHUh?=
LAMA-84NYfLSohmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrWcJZKSzVyPUOuOFkhdk1?MV7TRW5ITVJ?
MEG-01M1PMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2j1T2lEPTB;Mz60PUBvVQ>?NX3afpZQW0GQR1XS
LOXIMVIM4jYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHxUIlWUUN3ME2zMlUhdk1?MlvkV2FPT0WU
RPMI-8402NW\JZ5plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzpZnlKSzVyPUOuOUBvVQ>?NEnu[5BUSU6JRWK=
KARPAS-45M{nnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYWyUmpMUUN3ME2zMlU1KG6PM3jtXXNCVkeHUh?=
HCC1187Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rodWlEPTB;Mz61OEBvVQ>?MXrTRW5ITVJ?
MZ1-PCNFjCTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1T5fWlEPTB;Mz61OEBvVQ>?M{DlUnNCVkeHUh?=
no-11M{GyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTNwNUWgcm0>M1vhU3NCVkeHUh?=
EVSA-TNXP6WnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTNwNjDuUS=>MV;TRW5ITVJ?
DJM-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\lTI5KSzVyPUOuOlMhdk1?NH\4[lBUSU6JRWK=
COLO-684NXTCTplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrIUXliUUN3ME2zMlY3KG6PMkP1V2FPT0WU
NMC-G1NH;TcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\CTWM2OD1|Lk[4JI5OMVHTRW5ITVJ?
LC-1FM1G2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTNwN{Sgcm0>MV3TRW5ITVJ?
RL95-2NYi4VHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoKyTWM2OD1|Lke5JI5ONIq1RZVUSU6JRWK=
COLO-320-HSRMkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnmTWM2OD1|LkmyJI5OMmXxV2FPT0WU
RCC10RGBNFvXenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLHWldPUUN3ME2zMlk{KG6PMVPTRW5ITVJ?
HD-MY-ZM365fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG0OmZKSzVyPUOuPVMhdk1?MWfTRW5ITVJ?
NCI-H2141M2CxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S1emlEPTB;ND6wOUBvVQ>?NUK4fJQ4W0GQR1XS
K-562MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\NTWM2OD12LkGyJI5OMojJV2FPT0WU
NCI-H1648MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEm3NlBKSzVyPUSuNVMhdk1?M4D0TnNCVkeHUh?=
OMC-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTRwMUigcm0>NWDuc|dxW0GQR1XS
LB647-SCLCNYn3Rm5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPoTWM2OD12LkKyJI5OMXLTRW5ITVJ?
TE-12MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTvTWM2OD12LkK1JI5OMmHUV2FPT0WU
NOMO-1M1LkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonRTWM2OD12LkOzJI5ONIPyeHpUSU6JRWK=
RajiM1;qVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwNE[gcm0>Mn\1V2FPT0WU
NALM-6NV\XTWY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTRwNEmgcm0>NXPkVZp7W0GQR1XS
HL-60M{PTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITBRVVKSzVyPUSuOlchdk1?NIX0UJpUSU6JRWK=
IST-SL1Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXle5pRUUN3ME20MlY5KG6PNWLzWlNXW0GQR1XS
MHH-PREB-1NGnv[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUW3bFFEUUN3ME20Mlg3KG6PNGmxfINUSU6JRWK=
MHH-NB-11MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLqWVhJUUN3ME20MlkyKG6PMlfFV2FPT0WU
JiyoyeP-2003MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTVibl2=M{D1enNCVkeHUh?=
SBC-1NX3LemJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXCTWM2OD13LkCxJI5OMmPNV2FPT0WU
CHP-126NHLDdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHnTWM2OD13LkC2JI5OMXrTRW5ITVJ?
LU-139NGn6TmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDISHpKSzVyPUWuNVMhdk1?NGi5T5hUSU6JRWK=
NCI-SNU-5NHTROndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nON2lEPTB;NT6xO{BvVQ>?MkTMV2FPT0WU
SW962NGPFPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4f2[GlEPTB;NT6yNUBvVQ>?NYe0e49XW0GQR1XS
EW-1M{fWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTVwM{Ggcm0>M3rHVXNCVkeHUh?=
NCI-H1417NWmxdGFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTVwNUGgcm0>MoTYV2FPT0WU
LU-65NWjaSYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzPTWM2OD13Lki0JI5OMl\uV2FPT0WU
D-502MGM3rTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLkW5VKSzVyPU[uN|chdk1?MlLFV2FPT0WU
BC-3M4TL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\QRWlEPTB;Nj62NUBvVQ>?NYLoTo81W0GQR1XS
GDM-1M2K4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\DTWlEPTB;Nj63O{BvVQ>?NXPNeYFvW0GQR1XS
NCI-H2196M4nWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvVeIE3UUN3ME22Mlghdk1?NIr1bXJUSU6JRWK=
NB1M1zOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrOOJZKSzVyPU[uPFghdk1?MoPqV2FPT0WU
NCI-H345M1jzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjLXnBKSzVyPUeuNkBvVQ>?NFjVdpNUSU6JRWK=
SU-DHL-1MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrqeHR1UUN3ME23MlI1KG6PNWnSOZMzW0GQR1XS
JVM-2NIHyeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3lTHhKSzVyPUeuNlghdk1?M3zUZnNCVkeHUh?=
LU-134-ANUXFe3pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnqeI5KSzVyPUeuN|khdk1?NGTxXXBUSU6JRWK=
NCI-H1694MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHTTWM2OD15LkW4JI5ONHfTXIVUSU6JRWK=
NCI-SNU-16M1G4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTdwNkWgcm0>NHfncoxUSU6JRWK=
L-363NVXKfpVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTdwNzDuUS=>NE\WSotUSU6JRWK=
KG-1M2rzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVKzVodjUUN3ME23Mlk1KG6PMXXTRW5ITVJ?
MN-60NV23S4JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPETWM2OD16LkG0JI5ONHjxUXdUSU6JRWK=
NB6NYLwb|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X6SmlEPTB;OD60PEBvVQ>?MoHPV2FPT0WU
MLMANFPyVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDhSotKSzVyPUiuPFUhdk1?NHXSZ4JUSU6JRWK=
ATN-1NX7rXWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRThwOEmgcm0>MlXPV2FPT0WU
SK-NEP-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTlwMEGgcm0>M4nnTXNCVkeHUh?=
DMS-114NXfadZdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{S4cGlEPTB;OT62NkBvVQ>?NV\Nc2tyW0GQR1XS
CTB-1NGXDVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXvTWM2OD17Lk[3JI5OMl;QV2FPT0WU
NCI-H2081NXL5XJNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHzeWNKSzVyPUGwMlA6KG6PM3y2c3NCVkeHUh?=
ES5M{XvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXrTWM2OD1zMD6zPEBvVQ>?NF;Me|JUSU6JRWK=
HCC1599M{G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFf2SZpKSzVyPUGxMlkyKG6PMUDTRW5ITVJ?
NCI-H23MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfmNI03UUN3ME2xNk4yOiCwTR?=NXzORlVuW0GQR1XS
NCI-H1581NVvLXWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF{LkK4JI5OMlTDV2FPT0WU
JVM-3MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;OdGpKSzVyPUGyMlk6KG6PNWnHTZlRW0GQR1XS
NCI-SNU-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTF|LkG5JI5OMlnpV2FPT0WU
NB7M2jOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrhfmFKSzVyPUG1MlkzKG6PNV7Me49mW0GQR1XS
JARMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M170V2lEPTB;MU[uNVMhdk1?MoLjV2FPT0WU
TGWNFjPbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DYPGlEPTB;MU[uOFghdk1?M3HMTnNCVkeHUh?=
U-87-MGM2GySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LEfmlEPTB;MU[uO|Yhdk1?MX\TRW5ITVJ?
NCI-H1436MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTF5LkCxJI5ONVTVNoIxW0GQR1XS
GOTOMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDQfldKSzVyPUG3MlA3KG6PM1HtZ3NCVkeHUh?=
COLO-800NX7YOIhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTF5Lk[0JI5OM4DCZXNCVkeHUh?=
MFM-223MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFniWIhKSzVyPUG3MlkyKG6PMlHlV2FPT0WU
EW-18MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHETWM2OD1zNz65OkBvVQ>?NWjHOVNOW0GQR1XS
NB14Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrYTWM2OD1zNz65PEBvVQ>?NX\5[lVNW0GQR1XS
EB2M4T2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu4TWM2OD1zOD6wPEBvVQ>?NV\tV49RW0GQR1XS
EoL-1-M1jBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLDcZlKSzVyPUG4MlMyKG6PNYL1VpdJW0GQR1XS
NCCITNXPnOFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\pWFlKSzVyPUG4MlM3KG6PNVfBSnVxW0GQR1XS
DG-75NYrRbG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjmTWM2OD1zOD62NUBvVQ>?NWrDSHExW0GQR1XS
HCC2218Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXSd3lKSzVyPUG5MlUhdk1?NW\h[2o{W0GQR1XS
TE-6M{O5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFy0fYxKSzVyPUKwMlA5KG6PNHnaZldUSU6JRWK=
SF539MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnftTWM2OD1{MD62O{BvVQ>?MXPTRW5ITVJ?
NCI-H446NVvUXJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHvTWM2OD1{MT6xPEBvVQ>?NV7hb4d5W0GQR1XS
IST-MES1M1;1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLKTWM2OD1{Mj63O{BvVQ>?NFq5ZW9USU6JRWK=
NCI-H82MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJ|LkCyJI5OM4P6ZnNCVkeHUh?=
HCC2157MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPHTWM2OD1{Mz6xN{BvVQ>?MXrTRW5ITVJ?
EW-12M1rsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJ|LkG3JI5OM3j5PXNCVkeHUh?=
SIMANGTTcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HRcmlEPTB;MkOuN|ghdk1?MlXVV2FPT0WU
DOHH-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzOTWM2OD1{Mz60OUBvVQ>?Ml\QV2FPT0WU
IM-9M3iwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jiN2lEPTB;MkOuOVQhdk1?MmnyV2FPT0WU
EC-GI-10MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJ2LkKzJI5OM{nYeXNCVkeHUh?=
HDLM-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJ2LkW0JI5OM123OnNCVkeHUh?=
LS-1034MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\jTlI3UUN3ME2yOU44PSCwTR?=MYLTRW5ITVJ?
REHMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3aTWM2OD1{Nj60NUBvVQ>?NYXWPGJnW0GQR1XS
LU-165MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHnflBKSzVyPUK2MlczKG6PNGPLVWhUSU6JRWK=
NH-12M3\rVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHBTWM2OD1{Nz62O{BvVQ>?MUDTRW5ITVJ?
WSU-NHLNF\0eHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXDcYFKSzVyPUK4MlM6KG6PNG\IdmhUSU6JRWK=
ECC4MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrrTWM2OD1{OD63PUBvVQ>?NYLTe4hLW0GQR1XS
OCI-AML2NUTzVVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX0b41KSzVyPUK5MlY6KG6PMnrWV2FPT0WU
EW-3M3LMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4S4fWlEPTB;M{CuOVkhdk1?NUC1UoN3W0GQR1XS
NCI-H526MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTJTWM2OD1|Mj61OEBvVQ>?NUDiT5ZYW0GQR1XS
NCI-H719NELn[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTN2LkOxJI5ONUXQbFY6W0GQR1XS
KARPAS-422NF35PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\NTWM2OD1|NT6wOEBvVQ>?MYDTRW5ITVJ?
SK-MEL-1MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzMPXB6UUN3ME2zOU4yPyCwTR?=M{D3XnNCVkeHUh?=
ES3Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPRTIVKSzVyPUO1MlE6KG6PMWjTRW5ITVJ?
UACC-812NWHBcoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTN3LkS0JI5OMXTTRW5ITVJ?
C8166NEfTdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXxNVhKSzVyPUO1Mlchdk1?MnryV2FPT0WU
MDA-MB-134-VIMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTN3Lki3JI5OMkLhV2FPT0WU
D-283MEDNEDhVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTN5Lke5JI5OMUTTRW5ITVJ?
SHP-77M{jqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTN6LkCzJI5OMYLTRW5ITVJ?
NCI-H2227NF3ncFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3GwNmlEPTB;NECuOFkhdk1?MUfTRW5ITVJ?
SKM-1NILtWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEH4RlVKSzVyPUSyMlY{KG6PNWjr[3dUW0GQR1XS
L-428MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGGxUVRKSzVyPUSzMlg3KG6PM1;JZXNCVkeHUh?=
RPMI-6666MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTR3Lki5JI5OMkXuV2FPT0WU
NCI-H716NUDJSFluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M322eGlEPTB;NEiuPFEhdk1?MVTTRW5ITVJ?
DMS-79NYfp[WNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[yUmlEPTB;NUCuO|Ehdk1?NXfad2F6W0GQR1XS
RS4-11NFf3fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzUTWM2OD13MD64PEBvVQ>?Ml7EV2FPT0WU
NCI-H720M2GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWr1NG1TUUN3ME21NU4yOSCwTR?=MnfUV2FPT0WU
MC-CARM4f2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvPTWM2OD13MT61NkBvVQ>?MnzjV2FPT0WU
TALL-1M4nKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LHbGlEPTB;NUOuPVEhdk1?NVvLXGJ1W0GQR1XS
NCI-N87MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTV2LkG4JI5ONWqwfZRvW0GQR1XS
P30-OHKMmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;uTWM2OD13ND62NUBvVQ>?Mnz0V2FPT0WU
LP-1M2HuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLJfHg2UUN3ME22NU4zQCCwTR?=M1HkNnNCVkeHUh?=
YTNUC2cWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTZzLkigcm0>M3XpVHNCVkeHUh?=
MRK-nu-1M{\PV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jrOWlEPTB;NkGuPFIhdk1?MoP0V2FPT0WU
BT-474M1n6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEH5THlKSzVyPU[1JI5OM4\KbHNCVkeHUh?=
NCI-H322MMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTZ4LkGxJI5OM3PDWXNCVkeHUh?=
NCI-H128M2rmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTd2Lke3JI5OM{[0[HNCVkeHUh?=
KMS-12-PEMmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4mwSmlEPTB;N{[uNlQhdk1?NVW4c5M6W0GQR1XS
KP-N-YSNHfyenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW[3fWhLUUN3ME23Ok44PCCwTR?=M4nJR3NCVkeHUh?=
ALL-POMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7vUmxTUUN3ME23O{43PiCwTR?=NX64[m1[W0GQR1XS
EW-13NXj3NZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TkRmlEPTB;N{euO|Yhdk1?NW\aeY1zW0GQR1XS
EW-11M3WwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWj4WopxUUN3ME23PE42OiCwTR?=NYHtfWJUW0GQR1XS
SK-N-FINV;6VGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRThyLkKgcm0>MXvTRW5ITVJ?
CAL-148MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnWc5hIUUN3ME24NU45PCCwTR?=M3fkcnNCVkeHUh?=
RLNVrySGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DBPGlEPTB;OE[uNFkhdk1?NULmfIpTW0GQR1XS
AM-38M1y4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnUT2pKSzVyPUi4MlA5KG6PMVHTRW5ITVJ?
RH-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjFXGJpUUN3ME25PU45PSCwTR?=NYfH[5VPW0GQR1XS
NCI-H1770M4PLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUW5bHNXUUN3ME2xNFIvPDlibl2=NV3zcnR5W0GQR1XS
SIG-M5NILXVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;OSWpKSzVyPUGwOU4xPiCwTR?=M2DxV3NCVkeHUh?=
GR-STMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFzMz6zOEBvVQ>?MkC2V2FPT0WU
ST486MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTFzND6wOkBvVQ>?MoexV2FPT0WU
NCI-H1650M3H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLOZ5dKSzVyPUGxOU4zQSCwTR?=NWHiUVQ6W0GQR1XS
MHH-CALL-2NH:0TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1y4NmlEPTB;MUG1Mlchdk1?NFi2ZZBUSU6JRWK=
BV-173MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXi1e2Y1UUN3ME2xNlIvPzFibl2=NUS1[JJbW0GQR1XS
MC116Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTF2OD64OUBvVQ>?M2HUc3NCVkeHUh?=
NCI-H524MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHVUIRHUUN3ME2xOVkvOSCwTR?=M{nFZnNCVkeHUh?=
SCLC-21HM4Po[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTF3OT60NUBvVQ>?MlfkV2FPT0WU
NCI-H1304M4rMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTF4OT6yNUBvVQ>?NVX2PWVQW0GQR1XS
NCI-H510AMmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYi5b2dZUUN3ME2xPFUvOzdibl2=NIXzOVRUSU6JRWK=
NCI-H209M{jPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHwNG1qUUN3ME2xPVYvPTJibl2=M2Lw[XNCVkeHUh?=
KM-H2M13MT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLtdlZKSzVyPUG5O{4xPSCwTR?=NWW5WoF6W0GQR1XS
NCI-H1395M3zuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL2NpdwUUN3ME2yNVAvOTNibl2=MYfTRW5ITVJ?
NCI-H1155NVnZeldYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrsZndIUUN3ME2yN|AvOzJibl2=M2rtNnNCVkeHUh?=
COR-L279MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljsTWM2OD1{NUKuNVchdk1?NYXDSG5TW0GQR1XS
NCI-H1299NWHMbotVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJ4MT63NUBvVQ>?MXrTRW5ITVJ?
EW-22NV\YeVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnxTWM2OD1{NkOuO|Uhdk1?M2PsOnNCVkeHUh?=
SK-MEL-2M3Twfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGmxSmdKSzVyPUK4NU46KG6PM4e2T3NCVkeHUh?=
KASUMI-1M1y3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHPXGhKSzVyPUK4N{4xPSCwTR?=NESwcZBUSU6JRWK=
NCI-H187M2C5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\Ye455UUN3ME2yPFcvODhibl2=M3TTSnNCVkeHUh?=
NCI-H2171NFH1[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{K3NGlEPTB;Mki4MlkzKG6PNVnvZZJYW0GQR1XS
LNCaP-Clone-FGCNUTsWnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzRZ3F1UUN3ME2yPVUvOjZibl2=NF\3TI9USU6JRWK=
NCI-H1522NWGzS5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTNyNz6wOUBvVQ>?Ml;oV2FPT0WU
SCHNVHCVlFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DDdWlEPTB;M{KyMlIzKG6PM3Wz[XNCVkeHUh?=
THP-1M1v6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Hl[WlEPTB;M{KyMlYhdk1?MmHvV2FPT0WU
SNU-C1M{jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\kfotFUUN3ME2zOlIvODlibl2=NXrvNlV6W0GQR1XS
CA46NXXoRllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzRZ2hEUUN3ME2zO|MvPjNibl2=NFrodnJUSU6JRWK=
NCI-H1963NF3aV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLFXXJiUUN3ME2zPFYvOTlibl2=MlzKV2FPT0WU
DELMnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\4R3U1UUN3ME2zPVEvOjdibl2=MUXTRW5ITVJ?
TURNEXQU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jDdmlEPTB;M{m2MlYyKG6PMoHrV2FPT0WU
NCI-H226MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3qTWM2OD12MEOuNlMhdk1?M{DNSHNCVkeHUh?=
COLO-668MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z0UmlEPTB;NECzMlU4KG6PNX:5WmQzW0GQR1XS
CPC-NMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPTRldOUUN3ME20NFMvPzdibl2=M4nNe3NCVkeHUh?=
NCI-H889M3PSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DrVmlEPTB;NE[xMlkzKG6PMoXDV2FPT0WU
J-RT3-T3-5M1PrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHW4eY5KSzVyPUWzNk42PyCwTR?=M1G1OnNCVkeHUh?=
MSTO-211HNVX5e|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTV5ND6yOkBvVQ>?MmDrV2FPT0WU
SCC-15M{X2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vrWmlEPTB;Nk[3MlQ4KG6PMn3YV2FPT0WU
SUP-T1M{n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TqUGlEPTB;Nki2MlA1KG6PNYXSfWlnW0GQR1XS
DMS-153MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTibpRKSzVyPUe0Ok45OyCwTR?=MnHhV2FPT0WU
MS-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7qdGhKSzVyPUe1PU41OiCwTR?=NXXoXVBiW0GQR1XS
TC-YIKM3;5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljLTWM2OD15OEGuNFEhdk1?MWfTRW5ITVJ?
RPMI-8866NYDtU|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrmR5lKSzVyPUGwNFYvOjhizszNMl\hV2FPT0WU
KY821MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnXdm13UUN3ME2xNFM3NjB2IN88US=>MV3TRW5ITVJ?
P31-FUJNW\ENGpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHqzeXZKSzVyPUGxNVIvPzVizszNM2f6WnNCVkeHUh?=
COLO-824M{iwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXRe|QzUUN3ME2xNlYyNjd6IN88US=>M2DWV3NCVkeHUh?=
U-698-MMnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfzTWM2OD1{Mk[yMlE2KM7:TR?=MUnTRW5ITVJ?
TE-441-TNF7Z[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vEbGlEPTB;MkWyNU44KM7:TR?=M4jUb3NCVkeHUh?=
IMR-5NXyyNFRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnSTWM2OD1|NEC5MlYzKM7:TR?=M2\xZXNCVkeHUh?=
NCI-H1838M2DpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO1XJlKSzVyPUSxPFYvOzJizszNNWPQe4FXW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02658396 Not yet recruiting Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National  ...more Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) December 2016 Phase 1
NCT02811978 Not yet recruiting Multiple Myeloma Janssen Research & Development, LLC September 2016 Phase 3
NCT02840539 Not yet recruiting Mantle Cell Lymphoma Seoul National University Hospital|Consortium for Improvi  ...more Seoul National University Hospital|Consortium for Improving Survival of Lymphoma August 2016 Phase 2
NCT02719613 Recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie July 2016 Phase 2
NCT02755597 Recruiting Relapsed/Refractory Multiple Myeloma AbbVie|Genentech, Inc. July 2016 Phase 3

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Frequently Asked Questions

  • Question 1
    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

    Answer: S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us